14 studies found for:    CT-011
Show Display Options
RSS Create an RSS feed from your search for:
CT-011
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
Conditions: Melanoma;   Malignant Melanoma
Intervention: Drug: CT-011
2 Active, not recruiting Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma
Condition: Lymphoma
Interventions: Drug: CT-011;   Drug: Rituximab
3 Recruiting Gemcitabine and CT-011 for Resected Pancreatic Cancer
Conditions: Pancreatic Neoplasms;   Cancer of the Pancreas;   Neoplasms Pancreatic;   Pancreatic Cancer;   Pancreas Cancer
Interventions: Biological: CT-011;   Drug: Gemcitabine
4 Completed Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone Administered Intravenously to Patients With Colorectal Adenocarcinoma Previously Untreated for Metastatic Disease
Condition: Metastatic Colorectal Cancer
Interventions: Drug: CT-011;   Drug: FOLFOX
5 Recruiting Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer
Condition: Prostatic Neoplasms
Interventions: Drug: CT-011 (Anti-PD1 Antibody);   Other: Sipuleucel-T (provenge);   Drug: Cyclophosphamide
6 Active, not recruiting Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection
Condition: Chronic Hepatitis C
Intervention: Drug: CT-011
7 Terminated Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma
Condition: Primary Hepatocellular Carcinoma
Intervention: Drug: CT-011
8 Recruiting Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation
Condition: Multiple Myeloma
Interventions: Drug: CT-011;   Biological: Dendritic Cell Fusion Vaccine
9 Withdrawn CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors
Conditions: Breast Cancer;   Colon Cancer;   Pancreatic Cancer;   Sarcoma;   Ovarian Cancer
Interventions: Biological: p53: 264-272 peptide;   Drug: CT-011
10 Completed A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation
Conditions: Lymphoma, Large Cell, Diffuse;   Lymphoma, Mixed Cell, Diffuse;   Primary Mediastinal Large B-Cell Lymphoma;   Transformed Follicular Lymphoma;   Relapsed
Intervention: Drug: CT-011
11 Recruiting PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine
Condition: Renal Cell Carcinoma
Interventions: Drug: CT-011;   Biological: DC/RCC fusion vaccine
12 Recruiting Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission
Conditions: Acute Myelogenous Leukemia;   AML
Interventions: Biological: DC AML Vaccine;   Drug: CT-011
13 Recruiting Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma and Relapsed Glioblastoma Multiforme
Condition: Malignant Gliomas
Intervention: Biological: CT-011
14 Recruiting Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: lenalidomide;   Biological: pidilizumab;   Other: pharmacological study;   Other: laboratory biomarker analysis

Indicates status has not been verified in more than two years